$6.59 million Firm Commitment U.S. Initial Public Offering and NYSE American listing.
Highlights:
- NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults.
- The company is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities.
- IB-Stim is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old.
- Firm commitment underwritten initial public offering of 1,098,667 shares of common stock for $6.59 million US at $6.00 per share.
- Successfully closed $4M in bridge financing.
“The Exchange Listing team has been an invaluable tool over the years of working together toward this IPO. We are so grateful to the team for their unwavering support and expertise in helping us achieve this huge milestone that has the potential to impact many lives in the future” said Brian Carrico, President, and CEO”
Key Deliverables:
- Long standing partnership to successfully craft and execute an IPO Roadmap.
- Importantly facilitated the closing of several bridge financings.
- Managed all aspects of initial Nasdaq, and subsequent successful NYSE listing process and application.